Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 11.
doi: 10.1002/cncr.34571. Online ahead of print.

Differentially expressed messenger RNA/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection (pcRPLND) tissue

Tim Nestler  1   2 , Lara Kremer  1 , Melanie von Brandenstein  1 , Maike Wittersheim  3 , Pia Paffenholz  1 , Svenja Wagener-Ryczek  3 , Alexander Quaas  3 , Martin Hellmich  4 , Stefan Müller  5 , David Pfister  1 , Margarete Odenthal  3   6 , Axel Heidenreich  1   7
Affiliations

Differentially expressed messenger RNA/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection (pcRPLND) tissue

Tim Nestler et al. Cancer. .

Abstract

Background: Before postchemotherapy retroperitoneal lymph node dissection (pcRPLND), in patients with metastasized germ cell tumors (GCTs), those harboring necrosis (NEC) cannot be distinguished from those who have teratoma (TER), resulting in relevant overtreatment, whereas microRNA-371a-3p may be predictive for viable GCT. The purpose of this study was to explore messenger RNA (mRNA) and proteins to distinguish TER from NEC in pcRPLND tissue.

Methods: The discovery cohort consisted in total of 48 patients, including 16 each with TER, viable GCT, and NEC. Representative areas were microdissected. A NanoString panel and proteomics were used to analyze 770 genes and >5000 proteins. The most significantly and differentially expressed combination of both parameters, mRNA and its associated protein, between TER and NEC was validated using immunohistochemistry (IHC) in an independent validation cohort comprising 66 patients who were not part of the discovery cohort.

Results: The authors observed that anterior gradient protein 2 homolog (AGR2) and keratin, type I cytoskeletal 19 (KRT19) were significantly differentially expressed in TER versus NEC in mRNA and protein analyses (proteomics). The technical validation using IHC was successful in the same patients. These proteins were further validated by IHC in the independent patient cohort and exhibited significantly higher levels in TER versus NEC (p < .0001; area under the curve, 1.0; sensitivity and specificity, 100% each).

Conclusions: The current study demonstrated that KRT19 and AGR2 mRNA and protein are overexpressed in TER versus NEC in pcRPLND tissue and might serve as a future diagnostic target to detect TER, for instance, by functional imaging, to avoid overtreatment.

Plain language summary: The proteins and the corresponding genes called AGR2 and KRT19 can differentiate between teratoma and necrosis in remaining tumor masses after chemotherapy in patients who have metastasized testicular cancer. This may be a way to improve presurgical diagnostics and to reduce the current overtreatment of patients with necrosis only, who could be treated sufficiently by surveillance.

Keywords: messenger RNA (mRNA); necrosis; postchemotherapy retroperitoneal lymph node dissection (pcRPLND); proteomics; teratoma; testicular germ cell tumor.

References

REFERENCES

    1. Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1054-1068. doi:10.1016/j.eururo.2015.07.044
    1. Paffenholz P, Nestler T, Hoier S, Pfister D, Hellmich M, Heidenreich A. External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer. Urol Oncol. 2019;37(11):809.e9-809.e18. doi:10.1016/j.urolonc.2019.07.021
    1. Baessler B, Nestler T, Pinto Dos Santos D, et al. Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection. Eur Radiol. 2019;30(4):2334-2345. doi:10.1007/s00330-019-06495-z
    1. Dieckmann KP, Radtke A, Geczi L, et al. Serum levels of MicroRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol. 2019;37(16):1412-1423. doi:10.1200/JCO.18.01480
    1. Myklebust MP, Soviknes AM, Halvorsen OJ, Thor A, Dahl O, Raeder H. MicroRNAs in differentiation of embryoid bodies and the teratoma subtype of testicular cancer. Cancer Genomics Proteomics. 2022;19(2):178-193. doi:10.21873/cgp.20313